Epoch Investment Partners Inc. Purchases Shares of 364,219 Lantheus Holdings, Inc. $LNTH

Key Points

• Epoch Investment Partners Inc. invested approximately $35.55 million in Lantheus Holdings, acquiring 364,219 shares, which represents a 0.53% ownership in the company.
• Insider Farallon Partners L.L.C. sold 3,365,000 shares of Lantheus at an average price of $56.15, decreasing their position by 49.18%.
• Analysts have mixed ratings for Lantheus, with a consensus rating of "Moderate Buy" and an average target price of $105.50, reflecting several recent downgrades.

Epoch Investment Partners Inc. bought a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 364,219 shares of the medical equipment provider's stock, valued at approximately $35,548,000. Epoch Investment Partners Inc. owned about 0.53% of Lantheus at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in LNTH. Janus Henderson Group PLC increased its position in shares of Lantheus by 72.7% during the 4th quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider's stock valued at $554,583,000 after purchasing an additional 2,610,118 shares during the last quarter. Farallon Capital Management LLC increased its position in shares of Lantheus by 79.9% during the 4th quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider's stock valued at $475,590,000 after purchasing an additional 2,361,000 shares during the last quarter. TD Asset Management Inc increased its position in shares of Lantheus by 1,028.0% during the 1st quarter. TD Asset Management Inc now owns 682,614 shares of the medical equipment provider's stock valued at $66,623,000 after purchasing an additional 622,100 shares during the last quarter. Nuveen LLC bought a new position in shares of Lantheus during the 1st quarter worth $55,941,000. Finally, Assenagon Asset Management S.A. grew its stake in shares of Lantheus by 1,196.4% during the 1st quarter. Assenagon Asset Management S.A. now owns 336,237 shares of the medical equipment provider's stock worth $32,817,000 after acquiring an additional 310,301 shares during the period. 99.06% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Lantheus news, insider Rajiv A. Patel sold 3,365,000 shares of the firm's stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the sale, the insider owned 3,477,227 shares of the company's stock, valued at $195,246,296.05. This trade represents a 49.18% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Mary Anne Heino sold 26,066 shares of the firm's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the sale, the director directly owned 318,650 shares in the company, valued at approximately $24,481,879.50. The trade was a 7.56% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 6,838,066 shares of company stock worth $384,430,031 in the last quarter. 1.50% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. Truist Financial set a $63.00 price target on Lantheus and gave the stock a "hold" rating in a research note on Monday, August 11th. Mizuho cut their price target on Lantheus from $120.00 to $70.00 and set an "outperform" rating for the company in a research note on Thursday, August 7th. JMP Securities cut their price target on Lantheus from $112.00 to $73.00 and set a "market outperform" rating for the company in a research note on Thursday, August 7th. William Blair reiterated a "market perform" rating on shares of Lantheus in a research note on Wednesday, July 16th. Finally, Wall Street Zen upgraded Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $105.50.

Lantheus Price Performance

NASDAQ LNTH traded down $0.60 during trading hours on Friday, hitting $54.90. The company had a trading volume of 1,028,454 shares, compared to its average volume of 2,621,779. Lantheus Holdings, Inc. has a 52 week low of $47.25 and a 52 week high of $118.21. The firm has a 50 day simple moving average of $69.20 and a 200 day simple moving average of $83.19. The company has a debt-to-equity ratio of 0.49, a quick ratio of 4.07 and a current ratio of 4.29. The firm has a market capitalization of $3.73 billion, a price-to-earnings ratio of 14.60 and a beta of 0.14.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.08). Lantheus had a return on equity of 34.06% and a net margin of 17.82%.The company had revenue of $378.05 million during the quarter, compared to the consensus estimate of $389.69 million. During the same quarter in the prior year, the business earned $1.80 EPS. The firm's revenue for the quarter was down 4.1% compared to the same quarter last year. Equities research analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.